Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 54 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... September 6, 2023 News digest – HPV vaccine, 1 million breast screenings missed and... October 3, 2020 Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... November 26, 2024 Load more HOT NEWS Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ Reunión anual de la American Society of Clinical Oncology de 2021:... Surgery for Recurrent Ovarian Cancer Does Not Improve Survival Child With Cancer Becomes Honorary First Responder
